Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
批准号:
8717646
负责人:
ANDREW F. STEWART
金额:
$10.0万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-15 至 2015-06-30
关键词:
AdultAffectAmericanAnimalsAutomobile DrivingBeta CellCadaverCell CountCell CycleCell Cycle CheckpointCell Cycle RegulationCell TherapyCell physiologyCellsCellular biologyClinicalDataDiabetes MellitusGoalsHandHumanInsulinIslets of LangerhansKnowledgeLaboratoriesPathway interactionsPatientsPhenotypePhysiologyReagentRegulatory PathwayReplacement TherapyResearchResearch PersonnelResidual stateSafetySenior ScientistSourceStem cellsTherapeuticTreatment EfficacyWorkbeta cell replacementdiabetes mellitus therapyexperiencemembernovelpublic health relevancetechnology/technique
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): One of the principal goals of diabetes research is to generate a large and renewable supply of human insulin-producing beta cells for replacement therapy. Another is to understand how replacement or replenishment might be accomplished from endogenous, residual beta cells. One attractive and tractable approach is the induction of human beta cell replication, so that mature, differentiated human beta cells derived from endogenous sources, from cadaver pancreatic islets, or from the other sources (such as various types of stem cells or reprogrammed cells), might be expanded to numbers capable of treating large numbers of patients with diabetes. Whereas conventional dogma and widespread experience has suggested that adult human beta cells are terminally differentiated and cannot replicate, the investigators in this application have recently shown that this is not completely true. By manipulating cell cycle control, specifically the G1/S control checkpoint of the cell cycle, this group has shown that: a) human beta cells can be induced to replicate rapidly and still retain their differentiated, functional phenotype: and, b) that many direct and indirect, upstream options for human beta cell cycle activation exist. The goals of this application are to assemble a group of senior scientists who focus on all aspects of human beta cell biology and therapy, to facilitate and expedite human beta cell replication, differentiation and replacement strategies, and to share this expertise with the other members of the Beta Cell Biology Consortium (BCBC). The Specific Aims are: 1) To Fully Define The Normal Physiology, Mechanisms of Action, Therapeutic Efficacy and Safety of G1/S Cell Cycle Molecules In The Human Beta Cell. 2) To Explore the Regulatory Pathways Upstream Of The G1/S Checkpoint To Define Beta-Cell Specific Pathways To Activate Proliferation in Human Beta Cells. 3) To Share Knowledge, Data, Reagents, Animals, Technologies, and Techniques with Other BCBC Investigators. Data already in hand indicates that there are many novel ways to induce human beta cell replication, and that additional focus and refinement should help transform these approaches from laboratory bench research to human diabetes therapy.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10427406
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10267388
-
项目类别:
-
资助金额:$61.53万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
DREAM Complex Maintenance of Human Beta Cell Quiescence
-
批准号:10619645
-
项目类别:
-
资助金额:$61.44万
-
财政年份:2021
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8815293
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8636445
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8583716
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Pancreatic Islet Growth Factors: Transgenic and Viral Modeling
-
批准号:8470622
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2012
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8144434
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8636565
-
项目类别:
-
资助金额:$71.16万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8316307
-
项目类别:
-
资助金额:$15.99万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Pathophysiology of PTH-related Protein (1-36) in Humans
-
批准号:8068432
-
项目类别:
-
资助金额:$3.41万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:8655150
-
项目类别:
-
资助金额:$92.07万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
Multi-Disciplinary Approaches to Driving Therapeutic Human Beta Cell Replication
-
批准号:7993980
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2010
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION AND 125 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7139533
-
项目类别:
-
资助金额:$29.25万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION & 1,25 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7460757
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
MODELING BONE FORMATION & 1,25 VITAMIN D IN HUMORAL HYPERCALCEMIA OF MALIGNANCY
-
批准号:7260457
-
项目类别:
-
资助金额:$29.56万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
Modeling Bone Formation and 1,25 Vitamin D in Humoral Hypercalcemia of Malignancy
-
批准号:7650170
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2006
-
负责人:ANDREW F. STEWART
-
依托单位:
Renal Calcium Handling & 1, 25 Vitamin D Synthesis
-
批准号:6974659
-
项目类别:
-
资助金额:$5.62万
-
财政年份:2004
-
负责人:ANDREW F. STEWART
-
依托单位:
Anabolic Skeletal Agents for Osteoporosis
-
批准号:6754239
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2004
-
负责人:ANDREW F. STEWART
-
依托单位:
Islet Allograft Gene Therapy for Primate Diabetes
-
批准号:6803476
-
项目类别:
-
资助金额:$59.31万
-
财政年份:2003
-
负责人:ANDREW F. STEWART
-
依托单位:
海外基金